Findings

What do systematic reviews say?

2,079 questions · 2,112 findings · 171 reviews · Eyes and Vision

Sort:Best matchNewestHighest certainty Download CSV

No studies found 587 · 27.8%GRADE not reported 95 · 4.5%Very low 446 · 21.1%Low 557 · 26.4%Moderate 361 · 17.1%High 66 · 3.1%

Intervention not reported

Chorioretinitis · people living in communities affected by O.volvulus

The intervention showed no clear difference in chorioretinitis (low certainty).

1 finding from 1 review

Ivermectin for onchocercal eye disease (river blindness) 2012 · Cochrane Headline outcomes only
RR 1.75 [0.91, 3.37]
1 study · 528 participants
Low

Intervention not reported

Optic nerve disease · people living in communities affected by O.volvulus

The intervention showed no clear difference in optic nerve disease (low certainty).

1 finding from 1 review

Ivermectin for onchocercal eye disease (river blindness) 2012 · Cochrane Headline outcomes only
RR 0.78 [0.57, 1.06]
2 studies · 3577 participants
Low

Intervention not reported

Visual field loss · people infected with O.volvulus

1 finding from 1 review

Ivermectin for onchocercal eye disease (river blindness) 2012 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Intervention not reported

Punctate keratitis · people infected with O.volvulus

1 finding from 1 review

Ivermectin for onchocercal eye disease (river blindness) 2012 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 2 participants
GRADE not reported

Intervention not reported

Sclerosing keratitis · people infected with O.volvulus

The intervention showed no clear difference in sclerosing keratitis (low certainty).

1 finding from 1 review

Ivermectin for onchocercal eye disease (river blindness) 2012 · Cochrane Headline outcomes only
RR 0.06 [0, 1.23]
1 study · 39 participants
Low

Intervention not reported

Iridocyclitis · people infected with O.volvulus

1 finding from 1 review

Ivermectin for onchocercal eye disease (river blindness) 2012 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 2 participants
GRADE not reported

Intervention not reported

Chorioretinitis · people infected with O.volvulus

The intervention probably leads to lower chorioretinitis (moderate certainty).

1 finding from 1 review

Ivermectin for onchocercal eye disease (river blindness) 2012 · Cochrane Headline outcomes only
RR 0.02 [0, 0.32]
1 study · 200 participants
Moderate

Intervention not reported

Optic nerve disease · people infected with O.volvulus

1 finding from 1 review

Ivermectin for onchocercal eye disease (river blindness) 2012 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 354 participants
GRADE not reported

Intervention not reported

Visual impairment · people living in communities affected by O.volvulus

It is very uncertain whether the intervention changes visual impairment (very low certainty).

1 finding from 1 review

Ivermectin for onchocercal eye disease (river blindness) 2012 · Cochrane Headline outcomes only
RR 1.08 [0.33, 3.5]
1 study · 485 participants
Very low

Intervention not reported

Visual field loss · people living in communities affected by O.volvulus

The intervention leads to lower visual field loss (high certainty).

1 finding from 1 review

Ivermectin for onchocercal eye disease (river blindness) 2012 · Cochrane Headline outcomes only
RR 0.6 [0.41, 0.89]
1 study · 636 participants
High

Intervention not reported

Surgical failure (intraocular pressure >21mmHg) ( · patients with glaucoma surgery

The intervention probably leads to lower surgical failure (intraocular pressure >21mmHg) ( (moderate certainty).

1 finding from 1 review

Beta radiation for glaucoma surgery 2012 · Cochrane Headline outcomes only
RR 0.23 [0.14, 0.4]
4 studies · 561 participants
Moderate

Intervention not reported

Intraocular pressure ( · patients with glaucoma surgery

1 finding from 1 review

Beta radiation for glaucoma surgery 2012 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 123 participants
Low

Intervention not reported

Adverse effect: cataract · patients with glaucoma surgery

The intervention showed no clear difference in adverse effect: cataract (moderate certainty).

1 finding from 1 review

Beta radiation for glaucoma surgery 2012 · Cochrane Headline outcomes only
RR 1.79 [0.62, 5.14]
3 studies · 423 participants
Moderate

Sublingual immunotherapy vs placebo

Total ocular symptom scores Symptom scores · patients with allergic conjunctivitis

1 finding from 1 review

Sublingual immunotherapy for treating allergic conjunctivitis 2011 · Cochrane Headline outcomes only
no estimate extracted
36 studies · 3399 participants
Moderate

Sublingual immunotherapy vs placebo

Itchy/Gritty eyes Symptom scores · patients with allergic conjunctivitis

1 finding from 1 review

Sublingual immunotherapy for treating allergic conjunctivitis 2011 · Cochrane Headline outcomes only
no estimate extracted
28 studies · 3020 participants
Moderate

Sublingual immunotherapy vs placebo

Watery eyes Symptom scores · patients with allergic conjunctivitis

1 finding from 1 review

Sublingual immunotherapy for treating allergic conjunctivitis 2011 · Cochrane Headline outcomes only
no estimate extracted
21 studies · 2641 participants
Moderate

Sublingual immunotherapy vs placebo

Red eyes Symptom scores · patients with allergic conjunctivitis

1 finding from 1 review

Sublingual immunotherapy for treating allergic conjunctivitis 2011 · Cochrane Headline outcomes only
no estimate extracted
20 studies · 1211 participants
Moderate

Sublingual immunotherapy vs placebo

Eye drops Symptom scores · patients with allergic conjunctivitis

1 finding from 1 review

Sublingual immunotherapy for treating allergic conjunctivitis 2011 · Cochrane Headline outcomes only
no estimate extracted
13 studies · 1038 participants
Moderate

Sublingual immunotherapy vs placebo

Combined symptom‐medication scores Symptom scores · patients with allergic conjunctivitis

1 finding from 1 review

Sublingual immunotherapy for treating allergic conjunctivitis 2011 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 351 participants
Moderate

Sublingual immunotherapy vs placebo

Conjunctival immediate allergen sensitivity Symptom scores · patients with allergic conjunctivitis

1 finding from 1 review

Sublingual immunotherapy for treating allergic conjunctivitis 2011 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 250 participants
Moderate